ROYALTY PHARMA PLC- CL A (RPRX)

GB00BMVP7Y09 - Common Stock

30.45  +0.22 (+0.73%)

After market: 30.45 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (3/27/2024, 8:00:03 PM)

After market: 30.45 0 (0%)

30.45

+0.22 (+0.73%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap18.19B
Shares
PE6.95
Fwd PE7.93
Dividend Yield2.76%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RPRX Daily chart

Company Profile

Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 75 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Company Info

ROYALTY PHARMA PLC- CL A

110 East 59th Street

New York City NEW YORK 10022

P: 12128830200

CEO: Pablo Legorreta

Employees: 75

Website: https://www.royaltypharma.com

RPRX News

News Image17 hours ago - InvestorPlaceThe Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.

News Imagea month ago - Royalty Pharma plcRoyalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
News Imagea month ago - Royalty Pharma plcRoyalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s...

News Imagea month ago - The Motley FoolWall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Analysts are quite bullish about these beaten-down stocks.

News Imagea month ago - Seeking AlphaRoyalty Pharma reports Q4 results (NASDAQ:RPRX)

Royalty Pharma press release (RPRX): Q4 net income of $718M Revenue of $596M (+5.3% Y/Y) misses by $78.54M. More on Royalty Pharma Royalty Pharma: One Of The Be

News Imagea month ago - Royalty Pharma plcRoyalty Pharma Reports Q4 and Full Year 2023 Results

RPRX Twits

Here you can normally see the latest stock twits on RPRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example